A trial has shown a robust benefit for using neoadjuvant nivolumab plus ipilimumab in stage III melanoma. The treatment, a form of immunotherapy, appears to improve patient outcomes when used before surgery. Reports suggest this approach may be setting a new standard of care for melanoma, with some outlets noting durable survival outcomes and improved patient results.